IGF-I therapy in growth disorders.

Abstract excerpt

Patients with GH insensitivity, typically resulting from mutations affecting the GH receptor (GHR), GHR signaling cascade, or the IGF-I gene, are, generally, unresponsive to GH therapy. Beginning in the 1990s, clinical trials of IGF-I administration in such patients demonstrated both short- and long-term efficacy, although not to the degree observed with GH treatment of naïve GH-deficient patients. Adverse...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to GHR gene
• Share to Growth Disorders
• Share to Insulin-Like Growth Factor I